Kairos Pharma (NYSE American: KAPA) announced that President and Chief Scientific Officer Neil Bhowmick will present and moderate a discussion at the 24th Annual Discovery on Target Drug Discovery Conference, being held Sept. 28-Oct. 1 in Boston. Bhowmick will moderate a Sept. 30 breakout session titled “Winning the Race against Cancer Therapy Resistance,” focused on Kairos strategy of targeting cancer drug resistance to extend the efficacy of previously effective drug candidates.
Bhowmick will also deliver an oral plenary presentation Sept. 30 at 2:35 p.m. Eastern on KROS-101, Kairos drug candidate targeting solid tumors. The presentation will focus on KROS-101 targeting of GITR (“Glucocorticoid-Induced TNF Receptor”) to increase T-cell function and expand effector T-cells with anti-tumor activity.
To view the full press release, visit https://ibn.fm/DoHxL
About Kairos Pharma Ltd.
Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Kairos Pharma’s lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
NOTE TO INVESTORS: The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN